By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Morphotek Inc. 

210 Welsh Pool Road

Exton  Pennsylvania  19341  U.S.A.
Phone: 610-423-6100 Fax: n/a


Company News
Morphotek Announces Collaboration Agreement With The Johns Hopkins University To Research And Develop Novel Monoclonal Antibody-Based Therapies Targeting Missplicing-Associated Surface Antigens 9/6/2017 8:29:14 AM
Morphotek Announces An Agreement With Fujirebio Diagnostics, Inc. To Commercialize The CA125 II Assay As A Companion Diagnostic For Farletuzumab 9/5/2017 8:18:19 AM
Morphotek Announces Publication Uncovering One Of The Mechanisms By Which The Tumor-Produced CA125 Protein Suppresses Immune-Mediated Killing Via Farletuzumab 7/11/2017 8:56:04 AM
Morphotek Launches Antibody Drug Conjugate Services Business 4/3/2017 12:11:54 PM
Morphotek And Sandy Rollman Ovarian Cancer Foundation Launch Educational Resource On Clinical Trials 3/22/2017 10:44:31 AM
Morphotek And Eurofarma Laboratórios S.A. Sign Exclusive Licensing Agreement For Farletuzumab In Latin America 10/3/2016 8:06:43 AM
Morphotek Announces Sponsored Research Agreement With Fox Chase Cancer Center To Study Immunosuppressive Effects Of Tumor Shed Antigens To Improve Future Patient Therapies 9/13/2016 9:31:49 AM
Morphotek Announces Publication Of Phase 3 Results From Morab-003-004 Trial In Platinum-Sensitive Ovarian Cancer Patients 4/18/2016 10:36:36 AM
As part of Eisai Company (ESALY.PK)’s Strategic Plan, Morphotek Subsidiary Cuts 27 Jobs as Part of Restructuring 3/23/2016 7:08:03 AM
Morphotek Inc. Announces Collaboration With Mayo Clinic To Apply Its Folate Receptor Alpha Diagnostic Assays In A Phase II Clinical Trial In Triple-Negative Breast Cancer 2/3/2016 7:23:49 AM